title: Analysis of the cost-effectiveness of surfactant treatment (Curosurf®) in respiratory distress syndrome therapy in preterm infants: early treatment compared to late treatment.
abstract: BACKGROUND
  The best criteria for surfactant treatment in the perinatal period are unknown and this makes it of interest to consider the possible economic implications of lessening the use of more restrictive criteria.
  
  
  OBJECTIVE
  The objective of this study is the evaluation of the costs of respiratory care for preterm infants with Respiratory Distress Syndrome (RDS) treated with "early rescue" surfactant compared to a "late rescue" strategy.
  
  
  METHODS
  The study was carried out applying the costs of materials used, of staff and pharmacological therapy calculated in the Neonatal Intensive Care Unit (NICU) of an Italian hospital to the Verder et al. study (Pediatrics 1999) clinical data.
  
  
  RESULTS
  The cost for patients treated with early strategy was slightly lower than for patients treated with late strategy (Euro 4,901.70 vs. Euro 4,960.07). The cost of treatment with surfactant was greater in the early group (Euro 458.49 vs. Euro 311.74), but this was compensated by the greater cost of treatment with Mechanical Ventilation (MV) in the late group (respectively Euro 108.85 vs. Euro 259.25).
  
  
  CONCLUSIONS
  The cost-effectiveness analysis performed in this study shows how early treatment with surfactant in preterm infants with RDS, as well as being clinically more effective, is associated with a slightly lower cost.
authors.forename: Carlo
authors.initials: C
authors.lastname: Dani
authors.affiliation: PHarmES sas, Studi di valutazione economica, Milano, Italy. roberto.ravasio@pharmes.it.
authors.forename: Roberto
authors.initials: R
authors.lastname: Ravasio
authors.forename: Leonardo
authors.initials: L
authors.lastname: Fioravanti
authors.forename: Maria
authors.initials: M
authors.lastname: Circelli
mesh_terms: D001688:Biological Products / Q000008:administration & dosage* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D005260:Female; D005500:Follow-Up Studies; D017721:Hospital Costs / Q000706:statistics & numerical data*; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000191:economics / Q000628:therapy*; D008297:Male; D010743:Phospholipids / Q000008:administration & dosage* / Q000627:therapeutic use; D011663:Pulmonary Surfactants / Q000008:administration & dosage / Q000627:therapeutic use; D012121:Respiration, Artificial / Q000191:economics / Q000379:methods*; D012124:Respiratory Care Units / Q000191:economics*; D012127:Respiratory Distress Syndrome, Newborn / Q000191:economics / Q000628:therapy*; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D001688:Biological Products; D010743:Phospholipids; D011663:Pulmonary Surfactants; C068291:poractant alfa